FindTrial
Sign In

Role of Metheylergometrine in reducing blood loss in intrapartum C section

A RANDOMISED CONTROLLED TRIAL BETWEEN PROPHYLACTIC OXYTOCIN ALONG WITH METHYLERGOMETRINE VS OXYTOCIN ALONE TO REDUCE THE AMOUNT OF BLOOD LOSS IN INTRAPARTUM CAESAREAN SECTION - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076413
Enrollment
126
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O80- Encounter for full-term uncomplicated delivery

Interventions

Intervention1: METHYLERGOMETRINE with oxytocin: One amp methylergometrine 0.2mg/ml im to be given prophylactically during intrapartum cesarean section along woth oxytocin Control Intervention1: oxytoc

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: pregnant women undergoing intrapartum ceserean section period of gestation 37 weeks to 42 weeks singleton pregnancy

Exclusion criteria

Exclusion criteria: severe cardiac disease, uncontrolled hypertension, severe pre eclampsia, bleeding disorders obstructed labour allergy to methylergometrine multifetal gestation pre term or post term polyhydramnios

Design outcomes

Primary

MeasureTime frame
estimated reduction in blood loss by 300ml as compared to control groupTimepoint: 4 weeks and 2 months—

Secondary

MeasureTime frame
to assess the need for any additional uterotonic agents to assess any adverse event associated with methylergometrine to compare the duration of study in both the grouopsTimepoint: 4 weeks & 2 months—

Countries

India

Contacts

Public ContactMonica Shah

IPGMER and SSKM hospital

drgkamilya@gmail.com09831142720

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026